Exxel Pharma Revenue and Competitors
Employee Data
- Exxel Pharma has 4 Employees.
- Exxel Pharma grew their employee count by 0% last year.
Exxel Pharma's People
Name | Title | Email/Phone |
---|
Exxel Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 25 | 0% | N/A | N/A |
#2 | $10.3M | 40 | -5% | N/A | N/A |
#3 | $4.4M | 14 | -22% | N/A | N/A |
#4 | $195M | 122 | 0% | $121.4M | N/A |
#5 | $4.8M | 24 | -20% | N/A | N/A |
#6 | $6.8M | 24 | -14% | N/A | N/A |
#7 | $4.8M | 24 | 20% | N/A | N/A |
#8 | $4M | 40 | -11% | $138M | N/A |
#9 | $4.8M | 18 | -10% | N/A | N/A |
#10 | N/A | 82 | 22% | N/A | N/A |
What Is Exxel Pharma?
Exxel Pharma is a privately held company focused on developing novel therapeutics for the treatment of neuronal hypersensitivity disorders. The Company’s lead program, EX937, is a first-in-class, proprietary small molecule being developed for refractory chronic cough, a large underserved market with no current FDA-approved therapies, that affects approximately 10% of the global population. Leveraging a differentiated approach by inhibiting the FAAH enzyme, EX937 has demonstrated efficacy and favorable safety in its ability to modulate chronic cough in preclinical models. The Company is rapidly advancing the development of EX937 towards a first-in-human Phase 1/1b study. EX937 also has the potential to be utilized across a number of blockbuster indications, including hyperactive bladder, peripheral neuropathic pain and migraine headaches.
keywords:N/AN/A
Total Funding
4
Number of Employees
N/A
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.3M | 4 | 0% | N/A |
#2 | $0.2M | 4 | 33% | N/A |
#3 | $0.4M | 4 | -20% | N/A |
#4 | $0.3M | 4 | N/A | N/A |
#5 | $0.4M | 4 | -20% | N/A |